Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 7/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYBB | P04839 | 2/20 | 0.37 |
| ▸ | NOX3 | Q9HBY0 | 2/20 | 0.37 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MARK4 | Q96L34 | 9/20 | 0.34 |
| ▸ | PTPRB | P23467 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034451 | 0.87 | NOX1 (0.41) | NOX1GAAMAPTMEN1ALOX15 | |
| SCHEMBL1927571 | 0.86 | NOX1 (0.36) | NOX1GAAMAPTMEN1ALOX15 | |
| Hydrochloric Acid SCHEMBL6129195 | 0.76 | NOX1 (0.41) | NOX1GAAMAPTMEN1ALOX15 | |
| SCHEMBL4934512 | 0.75 | NOX1 (0.41) | NOX1GAAMAPTMEN1ALOX15 | |
| SCHEMBL1928027 | 0.75 | NOX1 (0.44) | NOX1GAAMAPTMEN1ALOX15 | |
| SCHEMBL1926715 | 0.75 | NOX1 (0.43) | NOX1GAAMAPTMEN1ALOX15 | |
| SCHEMBL1926935 | 0.74 | NOX1 (0.43) | NOX1GAAMAPTMEN1ALOX15 | |
| SCHEMBL4033771 | 0.74 | GRM1 (0.46) | NOX1GAAMAPTMEN1ALOX15 | |
| SCHEMBL1929067 | 0.74 | NOX1 (0.43) | NOX1GAAMAPTMEN1ALOX15 | |
| SCHEMBL1926490 | 0.74 | NOX1 (0.43) | NOX1GAAMAPTMEN1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288560-B2 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2012-10-16 | — | — | US | disclosed |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | IPSEN PHARMA S.A.S. (FR) | 2011-07-14 | — | — | US | disclosed |
| US-7956075-B2 | Thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives, e.g., butyl 2-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate inhibit lipidic peroxidation and monoamine oxidase and modulate sodium channels and are used for treating neurodegenerative disorders or pain. | IPSEN PHARMA S.A.S. (FR) | 2011-06-07 | — | — | US | disclosed |
| US-20080146627-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | LASSAUNIERE PIERRE-ETIENNE CHA | 2008-06-19 | — | — | US | disclosed |
| US-7291641-B2 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-11-06 | — | — | US | disclosed |
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-02-17 | — | — | US | disclosed |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OXER1, OPRL1, OPRK1 | NOX1 294/4885GAA 4465/4885MAPT 1601/4885 |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OPRK1, HCN1, P2RX7 | NOX1 331/4885GAA 3696/4885MAPT 1306/4885 |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | OXER1, OPRL1, CHRNA7 | NOX1 283/4885GAA 4369/4885MAPT 1207/4885 |
| US-20080146627-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OXER1, OPRL1, P2RX7 | NOX1 206/4885GAA 4117/4885MAPT 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.